Skip to main content

Vascular Closure

0
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Terumo Medical
Terumo MedicalGermany - Leverkusen
2 programs
Closure of the femoral arterial puncture siteN/A1 trial
Cross-Seal SystemN/A1 trial
Active Trials
NCT05335525Unknown230Est. May 2023
NCT03756558Completed147Est. Mar 2021
Abbott
AbbottABBOTT PARK, IL
1 program
Angio-Seal VIP 6 FrenchN/A1 trial
Active Trials
NCT01858636Completed235Est. Oct 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Terumo MedicalClosure of the femoral arterial puncture site
Terumo MedicalCross-Seal System
AbbottAngio-Seal VIP 6 French

Clinical Trials (3)

Total enrollment: 612 patients across 3 trials

NCT05335525Terumo MedicalClosure of the femoral arterial puncture site

Post-market Clinical Investigation of the Angio-Seal™ VIP VCD (ANGIO-SEAL CLOSE)

Start: Sep 2022Est. completion: May 2023230 patients
N/AUnknown
NCT03756558Terumo MedicalCross-Seal System

Cross-Seal Closure Device IDE Trial - Study of the Cross-SealTM Suture-Mediated Vascular Closure Device System

Start: Aug 2019Est. completion: Mar 2021147 patients
N/ACompleted
NCT01858636AbbottAngio-Seal VIP 6 French

Post-Market Study of the St. Jude Medical Angio-Seal™ V-Twist Integrated Platform (VIP) Vascular Closure Device

Start: May 2013Est. completion: Oct 2013235 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.